Daily Anesthesiology Research Analysis
Across anesthesiology and perioperative medicine, three studies stand out: a double-blind RCT shows that a single low-dose esketamine during surgical abortion markedly reduces first-night postoperative sleep disturbance; a pediatric RCT demonstrates capnography reduces oxygen desaturation during procedural sedation outside the OR; and a multicenter clinical validation establishes a tumor-cell depletion technology (CATUVAB) enabling safer intraoperative blood salvage in cancer surgery.
Summary
Across anesthesiology and perioperative medicine, three studies stand out: a double-blind RCT shows that a single low-dose esketamine during surgical abortion markedly reduces first-night postoperative sleep disturbance; a pediatric RCT demonstrates capnography reduces oxygen desaturation during procedural sedation outside the OR; and a multicenter clinical validation establishes a tumor-cell depletion technology (CATUVAB) enabling safer intraoperative blood salvage in cancer surgery.
Research Themes
- Perioperative pharmacology impacting recovery quality (esketamine and sleep)
- Monitoring innovation to prevent respiratory events in pediatric sedation (capnography)
- Oncologic blood management via intraoperative cell salvage with tumor-cell depletion (CATUVAB)
Selected Articles
1. Effect of a single low-dose esketamine administration during surgical abortion on postoperative sleep disturbance: a randomized controlled trial.
In a double-blind RCT of 204 women with baseline sleep disturbance undergoing surgical abortion, a single 0.2 mg/kg dose of esketamine at incision significantly reduced first-night postoperative sleep disturbance versus placebo (47.1% vs 71.6%; OR 0.35). No serious treatment-related adverse events were observed.
Impact: This is a well-designed randomized trial in a high-impact journal demonstrating a practical, low-dose intraoperative intervention that improves a common and consequential postoperative outcome: sleep disturbance.
Clinical Implications: For patients with pre-existing sleep disturbance undergoing brief gynecologic procedures, adding low-dose esketamine intraoperatively may improve early postoperative sleep without added serious safety concerns. This could be integrated into multimodal recovery pathways when individualized risk-benefit is favorable.
Key Findings
- Esketamine 0.2 mg/kg reduced first-night postoperative sleep disturbance (47.1% vs 71.6%; OR 0.35; 95% CI 0.20–0.64; P=0.0004).
- The trial was randomized, double-blind, placebo-controlled with 204 participants (102 per arm).
- No treatment-related serious adverse events occurred.
Methodological Strengths
- Randomized, double-blind, placebo-controlled design with adequate sample size
- Pre-registered trial with clearly defined primary outcome
Limitations
- Single clinical context (surgical abortion) limits generalizability to broader surgeries
- Outcome focused on first postoperative night without long-term follow-up
Future Directions: Assess dose-response, mechanism (e.g., analgesia, mood, sleep architecture), and generalizability across surgical populations, and evaluate longer-term sleep and recovery outcomes.
Women with pre-existing sleep disturbance frequently experience postoperative sleep disturbance after surgery. This randomized, double-blind, placebo-controlled, parallel-group trial was conducted to investigate the efficacy of intraoperative adjunctive esketamine administration in the reduction of postoperative sleep disturbance following surgical abortion for women with pre-existing sleep disturbance. 204 women who had sleep disturbance and were scheduled for elective surgical abortion were randomized in a one-to-one allocation ratio to receive either a single intravenous injection of 0.2 mg/kg of esketamine or placebo (saline) immediately after the beginning of surgery (102 women allocated to each group). This trial has now completed. The primary outcome, incidence of sleep disturbance on the first night after surgery, is significantly lower in the esketamine group than in the placebo group (47.1% [48 of 102] vs 71.6% [73 of 102]; odds ratio, 0.35; 95%CI, 0.20-0.64; P = 0.0004). No treatment-related serious adverse events were observed. Here we show that a single low dose of esketamine during surgical abortion improves postoperative sleep quality for women with pre-existing sleep disturbance. ClinicalTrials.gov identifier: NCT06388824.
2. Removal of EpCAM-positive tumor cells during intraoperative blood salvage- A pivotal multicenter clinical study (REMOVE).
In a multicenter clinical validation, CATUVAB® achieved sufficient depletion of EpCAM-positive tumor cells in 100% (95% CI 95.8–100%) of evaluable cases, with low residual catumaxomab levels and markedly reduced IL-6/IL-8 in erythrocyte concentrates. Findings support safe autologous reinfusion of salvaged blood during high-blood-loss cancer surgery.
Impact: This work addresses a longstanding barrier to intraoperative cell salvage in oncology by demonstrating reliable tumor-cell depletion, enabling broader, safer adoption of autologous transfusion strategies.
Clinical Implications: Anesthesiologists and perioperative teams can consider cell salvage with CATUVAB® during oncologic surgeries with high blood loss, potentially reducing allogeneic transfusion, immunologic risk, and costs while maintaining oncologic safety.
Key Findings
- Sufficient depletion of EpCAM-positive tumor cells was achieved in 100% (95% CI 95.8–100%; p<0.0001) of evaluable cases.
- Residual catumaxomab was below quantification in 89% (117/131) of erythrocyte concentrates.
- Inflammatory cytokines IL-6 and IL-8 were reduced 30–38-fold in erythrocyte concentrates versus intraoperative blood.
Methodological Strengths
- Multicenter clinical validation across diverse cancer surgeries
- Clear primary efficacy endpoint with confidence intervals and biomarker assessments
Limitations
- Non-randomized design limits causal inference on clinical outcomes
- Short-term laboratory endpoints; limited data on long-term oncologic outcomes
Future Directions: Prospective comparative studies evaluating clinical outcomes (transfusion rates, complications, recurrence) and cost-effectiveness versus standard care; expansion to other tumor types and health systems.
BACKGROUND: Intraoperative blood salvage can reduce the need for allogeneic blood transfusions, minimizing immunological risks and infection by reusing the patient's own blood. However, in cancer surgery, a key concern limiting its use is the potential reintroduction of viable cancer cells. Additional risks, such as infection and coagulopathy, have also contributed to its limited adoption. Irradiation of salvaged blood remains an option; however, it is time-intensive and may have detrimental effects on blood cells. These challenges highlight the need for improved technologies to enable safe application in oncological procedures. One such promising tool is CATUVAB®, which removes epithelial cell adhesion molecule (EpCAM)-positive tumor cells from salvaged blood. METHODS: In this multicenter, clinical validation study, patients undergoing major surgery for bladder cancer, gastric carcinoma, ovarian carcinoma, pancreatic carcinoma, colon/rectal carcinoma, non-small cell lung cancer, or peritoneal carcinomatosis were included. The primary objective of the study was to elucidate the efficacy of CATUVAB® in depleting intraoperatively salvaged blood of EpCAM-positive tumor cells. Secondary objectives included the determination of residual Catumaxomab antibody amount and cytokine levels in the final erythrocyte concentrate (EC). RESULTS: 203 patients were assessed for eligibility, and 80 were included in the safety analysis, of whom 61 had EpCAM-positive tumor cells in intraoperative blood. The primary efficacy analysis demonstrated a 100 % (95 % CI (95.8 %-100 %)) rate of sufficient depletion of EpCAM-positive tumor cells (p < 0.0001). In 117 out of 131 EC samples (89 %) the catumaxomab concentration was below the limit of quantification. Additionally, cytokines IL-6 and IL-8, typically due to surgical trauma, were significantly reduced (30- to 38-fold) in ECs compared to intraoperative blood. CONCLUSION: The study demonstrates the efficacy, safety and feasibility of CATUVAB® for the re-infusion of autologous EC processed by a cell salvage device during high-blood-loss cancer surgeries. These promising results have the potential to re-define the intraoperative blood salvage protocols in cancer surgeries.
3. Using capnography in children to prevent oxygen desaturation during procedural sedation: A randomised trial.
In an age-stratified randomized trial of 197 children sedated outside the OR, adding capnography to pulse oximetry reduced oxygen desaturation events (32.7% vs 15.6%; OR 0.38; P=0.005) and enabled earlier intervention at higher SpO2. Rates of severe desaturation did not differ.
Impact: Provides randomized evidence supporting routine capnography during pediatric procedural sedation outside the OR to prevent hypoxemia, informing monitoring standards and quality/safety protocols.
Clinical Implications: Pediatric sedation services should consider integrating capnography with pulse oximetry for earlier detection of ventilatory compromise and fewer desaturation episodes during procedures outside the operating room.
Key Findings
- Oxygen desaturation (≥5% drop from baseline) was lower with capnography (15.6%) vs control (32.7%); OR 0.38 (95% CI 0.19–0.75); P=0.005.
- SpO2 at intervention initiation was higher with capnography (93.8±7.8%) vs control (90.0±7.8%; P=0.003).
- No significant difference in severe desaturation (<90% or <85%).
Methodological Strengths
- Randomized, age-stratified design in a clinically relevant setting (outside OR)
- Predefined primary endpoint with effect size and confidence intervals
Limitations
- Unblinded design may introduce performance bias
- Single-center tertiary setting may limit generalizability
Future Directions: Evaluate cost-effectiveness, training/implementation strategies, and impact on severe hypoxemia and rescue events across diverse procedural environments.
BACKGROUND: Capnography is essential for ventilatory monitoring. OBJECTIVE: We evaluated the effects of capnography on the occurrence of oxygen desaturation in paediatric patients undergoing sedation outside the operating room. DESIGN: Age-stratified randomised controlled trial without blinding. SETTING: Tertiary care children's hospital. PATIENTS: We enrolled paediatric patients scheduled to undergo sedation outside the operating room with either oral chloral hydrate (25 to 50 mg kg -1 ), intravenous midazolam (0.1 mg kg -1 ), ketamine (1 mg kg -1 ) or a combination of these medications. INTERVENTION: Patients were allocated to the control and capnography groups that were monitored using pulse oximetry and pulse oximetry plus capnography. MAIN OUTCOME MEASURES: The primary outcome was the incidence of oxygen desaturation, defined as a decrease of at least 5% from the patient's baseline oxygen saturation. RESULTS: A total of 256 paediatric patients were screened for eligibility, and 214 were enrolled. Ultimately, data from 197 patients were analysed, with 101 and 96 children in the control and capnography groups, respectively. Oxygen desaturation occurred in 32.7% ( n = 33) and 15.6% ( n = 15) of the patients in the control and capnography groups, respectively, resulting in an odds ratio (OR) of 0.38 [95% confidence interval (CI), 0.19 to 0.75), P = 0.005]. The oxygen saturation at the time of intervention initiation was higher in the capnography group (93.8 ± 7.8%) compared with the control group (90 ± 7.8%, P = 0.003). The incidence of severe oxygen desaturation less than 90% or less than 85% did not differ between the two groups. CONCLUSION: Capnography significantly reduced the incidence of oxygen desaturation in paediatric patients undergoing procedural sedation outside the operating room. Our study advocates the integration of capnography with standard pulse oximetry to reduce the incidence of oxygen desaturation during paediatric procedural sedation outside the operating room. TRIAL REGISTRATION: Clinicaltrials.gov identifier: NCT04868266.